Exenatide: difference between revisions
Diff·revision 11 → 12·20:06, 19 Feb 2025
Difference between revision 11 and revision 12 of Exenatide. 11 lines changed; the page grew by 869 bytes.
| Revision 11 — 19:44, 29 Jan 2025 PurityClaimPia (talk) add the receptor targets to the lead sentence 3,419 bytes ±0 | Revision 12 — 20:06, 19 Feb 2025 Chromatokid (talk) add category for the drug class 4,288 bytes +869 | ||
|---|---|---|---|
| 28 | As a 39-residue synthetic peptide, exenatide is characterised by the ordinary battery for a synthetic peptide drug substance — chromatographic purity, [[Peptide content|peptide content]], water, counterion and related substances — rather than by the protein methods needed for a fusion construct.{{r|usp1503}} | 28 | As a 39-residue synthetic peptide, exenatide is characterised by the ordinary battery for a synthetic peptide drug substance — chromatographic purity, [[Peptide content|peptide content]], water, counterion and related substances — rather than by the protein methods needed for a fusion construct.{{r|usp1503}} |
| 29 | 29 | ||
| + | 30 | == The extended-release formulation == | |
| + | 31 | The weekly product suspends exenatide in biodegradable poly(lactide-co-glycolide) microspheres, which release peptide as the polymer hydrolyses. This is a formulation solution to a pharmacokinetic problem rather than a molecular one, and it behaves differently from a long-half-life molecule.{{r|drucker2018}} | |
| + | 32 | ||
| + | 33 | Concentrations rise slowly over six to seven weeks to a plateau, so the full effect of starting treatment is not seen for around two months, and concentrations decay over a comparable period after stopping. Neither the onset nor the offset can be accelerated. A distinctive injection-site nodule occurs in a substantial minority of recipients, attributable to the polymer matrix rather than to the peptide. | |
| + | 34 | ||
| 30 | == References == | 35 | == References == |
| 31 | {{reflist}} | 36 | {{reflist}} |
| ⋮ | ⋮ | ||
| 33 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 38 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| 34 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 39 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| + | 40 | ||
| + | 41 | == See also == | |
| + | 42 | * [[GLP-1 receptor agonist]] | |
| + | 43 | * [[Lixisenatide]] | |
| + | 44 | * [[Liraglutide]] | |
| + | 45 | * [[Dipeptidyl peptidase-4]] | |
| 35 | 46 | ||
| 36 | {{DEFAULTSORT:Exenatide}} | 47 | {{DEFAULTSORT:Exenatide}} |